Current and emerging treatments for immune thrombocytopenia

References

• Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–180.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207.
   PubMed Web of Science ®Google Scholar
• Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133(4):364–374.
   PubMed Web of Science ®Google Scholar
• Audia S, Mahevas M, Samson M, et al. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620–632.
   PubMed Web of Science ®Google Scholar
• Bakchoul T, Sachs UJ. Platelet destruction in immune thrombocytopenia. Understanding the mechanisms. Hamostaseologie. 2016;36(3):187–194.
   PubMed Web of Science ®Google Scholar
• Bromberg ME. Immune thrombocytopenic purpura – the changing therapeutic landscape. N Engl J Med. 2006;355(16):1643–1645.
   PubMed Web of Science ®Google Scholar
• Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–596.
   PubMed Web of Science ®Google Scholar
• Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–5995.
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–2634.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Porras JR, Escalante F, Pardal E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol. 2013;91(3):236–241.
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018;131(11):1172–1182.
   PubMed Web of Science ®Google Scholar
• Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77(7):1117–1124.
   PubMed Web of Science ®Google Scholar
• Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369(6481):565–568.
   PubMed Web of Science ®Google Scholar
• Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106(2):345–356.
   PubMed Web of Science ®Google Scholar
• Broudy VC, Lin NL, Sabath DF, et al. Human platelets display high-affinity receptors for thrombopoietin. Blood. 1997;89(6):1896–1904.
   PubMed Web of Science ®Google Scholar
• Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018;2(4):454–461.
   PubMed Web of Science ®Google Scholar
• Mitchell WB, Bussel JB. Thrombopoietin receptor agonists: a critical review. Semin Hematol. 2015;52(1):46–52.
   PubMed Web of Science ®Google Scholar
• Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93(3):704–706.
   PubMed Web of Science ®Google Scholar
• Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87(10):4068–4071.
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241–3248.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247.
   PubMed Web of Science ®Google Scholar
• Gibiansky E, Zhang J, Williams D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51(6):842–856.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641–648.
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–2536. Blood, 131 (6),709 (2018).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez TJ, Pascual C, Alvarez-Roman MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40–43.
   PubMed Web of Science ®Google Scholar
• Bussel JB, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315–325.
   PubMed Web of Science ®Google Scholar
• Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649–1658.
   PubMed Web of Science ®Google Scholar
• Vlachodimitropoulou E, Chen YL, Garbowski M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood. 2017;130(17):1923–1933.
   PubMed Web of Science ®Google Scholar
• Lambert MP, Witmer CM, Kwiatkowski JL. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Am J Hematol. 2017;92(6):E88–e91.
   PubMed Web of Science ®Google Scholar
• Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386–394.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607–4616.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672–1681.
   PubMed Web of Science ®Google Scholar
• Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76(6):628–638.
   PubMed Web of Science ®Google Scholar
• Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006;135(4):547–553.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Hsieh L, Buchanan GR, et al. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2015;62(2):208–213.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28–36.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45–54.
   PubMed Web of Science ®Google Scholar
• Moulis G, Bagheri H, Sailler L, et al. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment. Eur J Intern Med. 2014;25(8):777–780.
   PubMed Web of Science ®Google Scholar
• Vishnu P, Aboulafia DM. Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. J Blood Med. 2016;7:99–106.
   PubMedGoogle Scholar
• Kuter DJ. Romiplostim. Cancer Treat Res. 2011;157:267–288.
   PubMedGoogle Scholar
• Bussel JB. Avatrombopag. Br J Haematol. 2018;183(3):342–343.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–3894.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479–490.
   PubMed Web of Science ®Google Scholar
• Shirley M. Avatrombopag: first global approval. Drugs. 2018;78(11):1163–1168.
   Google Scholar
• Freson K, Hashimoto H, Thys C, et al. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. J Clin Invest. 2004;113(6):905–912.
   PubMed Web of Science ®Google Scholar
• Freson K, Peeters K, De Vos R, et al. PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications. Blood. 2008;111(4):1885–1893.
   PubMed Web of Science ®Google Scholar
• Peeters K, Loyen S, Van Kerckhoven S, et al. Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis. Br J Haematol. 2010;151(1):54–61.
   PubMed Web of Science ®Google Scholar
• Santini V, Giles FJ. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica. 1999;84(11):1035–1042.
   PubMed Web of Science ®Google Scholar
• Fan H, Zhu HL, Li SX, et al. Efficacy of amifostine in treating patients with idiopathic thrombocytopenia purpura. Cell Biochem Biophys. 2011;59(1):7–12.
   PubMed Web of Science ®Google Scholar
• Fan H, Zhu HL, Li SX, et al. [Therapy of 17 cases of idiopathic thrombocytopenia purpura by amifostine]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16(1):192–196.
   PubMedGoogle Scholar
• Newland A, Lee EJ, McDonald V, et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9–25.
   PubMed Web of Science ®Google Scholar
• Crowley MT, Costello PS, Fitzer-Attas CJ, et al. A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J Exp Med. 1997;186(7):1027–1039.
   PubMed Web of Science ®Google Scholar
• Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319(3):998–1008.
   PubMed Web of Science ®Google Scholar
• Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113(14):3154–3160.
   PubMed Web of Science ®Google Scholar
• Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–930.
   PubMed Web of Science ®Google Scholar
• Rolf MG, Curwen JO, Veldman-Jones M, et al. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015;3(5):e00175.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Genovese MC, Ho M, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014;66(12):3255–3264.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578–2585.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Bartlett NL, Blum KA, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016;54:11–17.
   PubMed Web of Science ®Google Scholar
• Pyzik M, Rath T, Lencer WI, et al. FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol (baltimore, Md: 1950). 2015;194(10):4595–4603.
   PubMed Web of Science ®Google Scholar
• Christianson GJ, Sun VZ, Akilesh S, et al. Monoclonal antibodies directed against human FcRn and their applications. mAbs. 2012;4(2):208–216.
   PubMed Web of Science ®Google Scholar
• Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. mAbs. 2018;10(7):1111–1130.
   PubMed Web of Science ®Google Scholar
• Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9:414.
   Web of Science ®Google Scholar
• Zuercher AW, Spirig R, Baz Morelli A, et al. IVIG in autoimmune disease – potential next generation biologics. Autoimmun Rev. 2016;15(8):781–785.
   PubMed Web of Science ®Google Scholar
• Jain A, Olsen HS, Vyzasatya R, et al. Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. Arthritis Res Ther. 2012;14(4):R192.
   PubMed Web of Science ®Google Scholar
• Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med. 1986;314(19):1236–1239.
   PubMed Web of Science ®Google Scholar
• Flaherty MM, MacLachlan TK, Troutt M, et al. Nonclinical evaluation of GMA161 – an antihuman CD16 (FcgammaRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. Toxicol Sci. 2012;125(1):299–309.
   PubMed Web of Science ®Google Scholar
• Yu X, Menard M, Prechl J, et al. Monovalent Fc receptor blockade by an anti-Fcgamma receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity. Blood. 2016;127(1):132–138.
   PubMed Web of Science ®Google Scholar
• Sondermann P. The FcgammaR/IgG Interaction as target for the treatment of autoimmune diseases. J Clin Immunol. 2016;36(Suppl 1):95–99.
   PubMedGoogle Scholar
• Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood. 2005;105(1):215–218.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood. 2004;103(4):1229–1236.
   PubMed Web of Science ®Google Scholar
• Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141(4):545–548.
   PubMed Web of Science ®Google Scholar
• Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.
   Web of Science ®Google Scholar
• Mirabet M, Barrabes JA, Quiroga A, et al. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol Immunol. 2008;45(4):937–944.
   PubMed Web of Science ®Google Scholar
• Crow AR, Song S, Suppa SJ, et al. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Blood. 2011;117(3):971–974.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Peng J, Sun JZ, et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost. 2008;6(1):158–165.
   PubMed Web of Science ®Google Scholar
• Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica. 2007;92(2):283–284.
   PubMed Web of Science ®Google Scholar
• Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6:7737.
   PubMed Web of Science ®Google Scholar
• Tao L, Zeng Q, Li J, et al. Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia. J Hematol Oncol. 2017;10(1):46.
   PubMedGoogle Scholar
• Zhang XH, Wang QM, Zhang JM, et al. Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. J Hematol Oncol. 2015;8:116.
   PubMed Web of Science ®Google Scholar
• Shao L, Wu Y, Zhou H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets. 2015;26(5):495–497.
   PubMed Web of Science ®Google Scholar
• Alioglu B, Tasar A, Ozen C, et al. An experience of oseltamivir phosphate (tamiflu) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report. Pathophysiol Haemost Thromb. 2010;37(2–4):55–58.
   PubMedGoogle Scholar
• Jansen AJ, Peng J, Zhao HG, et al. Sialidase inhibition to increase platelet counts: a new treatment option for thrombocytopenia. Am J Hematol. 2015;90(5):E94–95.
   PubMed Web of Science ®Google Scholar
• Revilla N, Corral J, Minano A, et al. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets ;2019;30(6):743–751.
   PubMed Web of Science ®Google Scholar
• Ding L, Saunders TL, Enikolopov G, et al. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481(7382):457–462.
   PubMed Web of Science ®Google Scholar
• Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505(7483):327–334.
   PubMed Web of Science ®Google Scholar
• Rafii S, Shapiro F, Pettengell R, et al. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood. 1995;86(9):3353–3363.
   PubMed Web of Science ®Google Scholar
• Psaila B, Lyden D, Roberts I. Megakaryocytes, malignancy and bone marrow vascular niches. J Thromb Haemost. 2012;10(2):177–188.
   PubMed Web of Science ®Google Scholar
• Kong Y, Cao XN, Zhang XH, et al. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood. 2018;131(11):1219–1233.
   PubMed Web of Science ®Google Scholar
• Shi MM, Kong Y, Song Y, et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood. 2016;128(25):2988–2999.
   PubMed Web of Science ®Google Scholar